Neuroscience

Developing preclinical animal models that faithfully mimic the progressive nature of Parkinson’s disease (PD) is crucial for advancing mechanistic insights as well as therapeutic discovery. While recombinant adeno-associated virus (rAAV)-driven α-synuclein overexpression is widely used, its reliance on high viral titers introduces nonspecific toxicity and limits physiological relevance. The SynFib model, which combines modest rAAV-driven α-synuclein expression (Syn) with α-synuclein preformed fibril (PFF) seeding (Fib), has shown promise in reproducing PD-like pathology. However, current implementations of this SynFib model have largely been confined to rats and require sequential surgeries, which increase animal distress and reduce reproducibility. Here, we present a streamlined protocol to generate a SynFib mouse model of PD that integrates rAAV-α-synuclein delivery and PFF injection into a single stereotaxic surgery. Using fine glass capillaries, this method prevents backflow of injected material, reduces injection-induced trauma, minimizes neuroinflammation, and ensures robust lesion development. This streamlined mouse model provides a reproducible and practical system to investigate α-synuclein-associated pathology and serves as a versatile platform for preclinical testing of potential therapeutics for PD.

Detecting the proliferation of cells with copper(I)-catalyzed azide-alkyne cycloaddition (click chemistry) and the thymidine analogue, 5-ethynyl-2’-deoxyuridine (EdU), is a simpler and more versatile method than traditional antibody-based approaches. Instead of the harsh series of steps typically used for 5-bromo-2’-deoxyuridine (BrdU) detection, detecting EdU does not require DNA denaturation and is suitable for use with other applications. This approach was implemented in an animal model of ischemic stroke. The following protocol details how to use EdU to label, track, and visualize leukocyte recruitment for flow cytometry and fluorescence microscopy, including the processes for EdU injection and blood and tissue sample preparation. Considerations for timing, dosing, and cell viability are also outlined to tailor the protocol to experimental needs. This method could be applied to various models that require extended tracking periods, as the signal from EdU can last several cell divisions, depending on cell type and condition.

Small fiber neuropathy (SFN) is an underdiagnosed condition characterized by sensory and autonomic dysfunction due to impairment of small nerve fibers in skin, blood vessels, and internal organs. Various underlying disorders are associated with SFN, and the pathophysiology of nerve fiber damage and functional impairment is the subject of extensive research. Diagnosis of SFN is challenging as standard electrodiagnostic techniques assess large fiber function and therefore are normal in SFN patients. The current gold standard for SFN diagnosis in humans is a skin biopsy, commonly obtained from the distal leg, hairy skin region, with evaluation of intraepidermal nerve fiber density (IENFD) using protein gene product 9.5 (PGP9.5) immunolabeling. While well-established in clinical practice, equivalent standardized, reproducible methods for assessing IENFD in experimental mouse models are lacking, which limits translational research in this field. Previous work in mice has relied on diverse antibodies, variable tissue sampling, and the use of confocal microscopy to trace nerve fibers. Other approaches have used chromogenic precipitate-based staining, which limits the ability to co-label multiple proteins. Here, we present a detailed, simple, and reproducible protocol for IENFD quantification of small nerves in the distal glabrous skin of the mouse hind paw. This protocol uses the two distal footpads, ensuring consistent sampling across animals. Prior to sectioning, the tissue is fixed and cryoprotected. Serial 20-μm sections are mounted on glass slides, dried, permeabilized, blocked, and immunostained with an anti-PGP9.5 monoclonal antibody, and then detected by binding secondary fluorescent-labeled antibodies. Although murine hairy skin analysis may apparently show a higher translational value, as it better reflects human biopsy sites, it is compromised by dense hair shafts and follicles, which interrupt epidermis continuity and thus interfere with sampling consistency. Polyneuropathy sensory symptoms, in fact, begin at the most distal sensory site, which is the glabrous skin of the toes. Thus, evaluation of this anatomical location best represents the clinical realm and may have the best sensitivity for identifying early axonal changes. In this protocol, we focused on IENFD quantification as done in human samples. Mechanoreceptors such as Meissner corpuscles are detectable and quantifiable by this method, and represent additional value since pressure-evoked pain, transmitted by these, is often reported by affected individuals. This immunolabeling protocol can be completed within one day [involving a small number of animals, where all three stages can be performed during a long working day (approximately 12 h)], while the entire workflow, including fixation and cryoprotection, is completed in up to 72 h. Importantly, the dermal and epidermal small fibers can be visualized using a standard fluorescence microscope, thereby avoiding the need for confocal imaging while maintaining high reproducibility. Preliminary validation in several animal models of inflammatory neuropathy and pain demonstrated a reproducible approximately 50% reduction in IENFD compared to controls, reaching statistical significance with n = 4 per group. This method supports SFN research and preclinical evaluation of novel therapeutics.

Microglia, the resident immune cells of the central nervous system, play a crucial role in maintaining neural homeostasis and in regulating neurodevelopment, neuroinflammation, tissue repair, and neurotoxicity. They are also key contributors to the pathogenesis of various neurodegenerative disorders, underscoring the need for in vitro models that accurately recapitulate disease-relevant conditions. Among the available isolation methods, the classical mixed glial culture shaking technique remains the most commonly employed, while alternatives such as magnetic bead separation and fluorescence-activated cell sorting (FACS) offer higher purity but are often constrained by technical complexity and cost. In this study, we refined the traditional shaking method by supplementing specific cytokines during culture to enhance microglial viability and proliferation. Our optimized protocol produced primary microglia with higher purity, greater yield, and improved viability compared with the conventional approach, thereby increasing experimental efficiency while substantially reducing time, animal usage, and overall cost.

Characterizing the morphology of amyloid proteins is an integral part of studying neurodegenerative diseases. Such morphological characterization can be performed using atomic force microscopy (AFM), which provides high-resolution images of the amyloid protein fibrils. AFM is widely employed for visualizing mechanical and physical properties of amyloid fibrils, not only from a biological and medical perspective but also in relation to their nanotechnological applications. A crucial step in AFM imaging is coating the protein of interest onto a substrate such as mica. However, existing protocols for this process vary considerably. The conventional sample preparation method often introduces artifacts, particularly due to deposition of excess salt. Hence, an optimized protocol is essential to minimize salt aggregation on the mica surface. Here, we present an optimized protocol for coating amyloid proteins onto mica using the dip-washing method to eliminate background noise. This approach improves the adherence of protein to the mica surface while effectively removing residual salts.

Research on brain disorders, particularly in the field of oncology, requires in vivo models to evaluate various therapeutic approaches, including intracerebral drug delivery. To meet this requirement, the implantation of intracerebral cannulas offers a reliable method for administering candidate therapeutics directly into the brain. This protocol describes a surgical technique for cannula implantation in mice, enabling repeated administration of therapeutic compounds in the context of glioblastoma treatment. The method was designed with an emphasis on using accessible, easy-to-handle, and sterilized tools to optimize surgical outcomes. Particular attention was also given to animal welfare, notably through refined procedures for asepsis, anesthesia, and postoperative care.

Telomere length maintenance is strongly linked to cellular aging, as telomeres progressively shorten with each cell division. This phenomenon is well-documented in mitotic, or dividing, cells. However, neurons are post-mitotic and do not undergo mitosis, meaning they lack the classical mechanisms through which telomere shortening occurs. Despite this, neurons retain telomeres that protect chromosomal ends. The role of telomeres in neurons has gained interest, particularly in the context of neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS), where aging is a major risk factor. This has sparked interest in investigating telomere maintenance mechanisms in post-mitotic neurons. Nevertheless, most existing telomere analysis techniques were developed for and optimized using mitotic cells, posing challenges for studying telomeres in non-dividing neuronal cells. Thus, this protocol adapts an already established technique, the combined immunofluorescence and telomere fluorescent in situ hybridization (IF-FISH) on mitotic cells to study the processes occurring at telomeres in cortical neurons of the mouse ALS transgenic model, TDP-43 rNLS. Specifically, it determines the occurrence of DNA damage and the alternative lengthening of telomeres (ALT) mechanism through simultaneous labeling of the DNA damage marker, γH2AX, or the ALT marker, promyelocytic leukemia (PML) protein, together with telomeres. Therefore, the protocol enables the visualization of DNA damage (γH2AX) or the ALT marker (PML) concurrently with telomeres. This technique can be successfully applied to brain tissue and enables the investigation of telomeres specifically in cortical neurons, rather than in bulk tissue, offering a significant advantage over Southern blot or qPCR-based techniques.

Human induced pluripotent stem cell (hiPSC)-derived motor neurons (MNs) provide a critical source for the study of motor neuron diseases (MNDs), which has been hindered by the lack of appropriate disease models for many years. Although many spinal MN differentiation protocols have been established by mimicking in vivo neurogenesis using extrinsic signaling molecules, substantial variations in the duration and efficiency persist due to inconsistencies in concentrations, timing, and delivery methods of these molecules. Here, we present an efficient monolayer culture differentiation strategy that enables the generation of enriched CHAT⁺ spinal MNs (sMNs) in 18 days and functional sMNs exhibiting extensive network activities, as confirmed by multielectrode array (MEA), within 28 days. Therefore, this optimized MN differentiation protocol facilitates the production of mature sMNs for MND research, high-throughput drug screening, and potential cell replacement therapies.

An improved correlative light and electron microscopy (CLEM) method has recently been introduced and successfully employed to identify and analyze protein inclusions in cultured cells as well as pathological proteinaceous deposits in postmortem human brain tissues from individuals with diverse neurodegenerative diseases. This method significantly enhances antigen preservation and target registration by replacing conventional dehydration and embedding reagents. It achieves an optimal balance of sensitivity, accuracy, efficiency, and cost-effectiveness compared to other current CLEM approaches. However, due to space constraints, only a brief overview of this method was provided in the initial publication. To ensure reproducibility and facilitate widespread adoption, the author now presents a detailed, step-by-step protocol of this optimized CLEM technique. By enhancing usability and accessibility, this protocol aims to promote broader application of CLEM in neurodegenerative disease research.

Proper brain function depends on the integrity of the blood–brain barrier (BBB), which is formed by a specialized network of microvessels in the brain. Reliable isolation of these microvessels is crucial for studying BBB composition and function in both health and disease. Here, we describe a protocol for the mechanical dissociation and density-based separation of microvessels from fresh or frozen human and murine brain tissue. The isolated microvessels retain their molecular integrity and are compatible with downstream applications, including fluorescence imaging and biochemical analyses. This method enables direct comparisons across species and disease states using the same workflow, facilitating translational research on BBB biology.